325 related articles for article (PubMed ID: 8608781)
1. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls.
Spencer CA; Wang CC
Endocrinol Metab Clin North Am; 1995 Dec; 24(4):841-63. PubMed ID: 8608781
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
[TBL] [Abstract][Full Text] [Related]
3. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
Spencer CA; Takeuchi M; Kazarosyan M; Wang CC; Guttler RB; Singer PA; Fatemi S; LoPresti JS; Nicoloff JT
J Clin Endocrinol Metab; 1998 Apr; 83(4):1121-7. PubMed ID: 9543128
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas.
Spencer CA; Bergoglio LM; Kazarosyan M; Fatemi S; LoPresti JS
J Clin Endocrinol Metab; 2005 Oct; 90(10):5566-75. PubMed ID: 15985472
[TBL] [Abstract][Full Text] [Related]
5. [Recovery test or immunoradiometric measurement of anti-thyroglobulin autoantibodies for interpretation of thyroglobulin determination in the follow-up of different thyroid carcinoma].
Zöphel K; Wunderlich G; Liepach U; Koch R; Bredow J; Franke WG
Nuklearmedizin; 2001 Oct; 40(5):155-63. PubMed ID: 11727628
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
7. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
8. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
9. [Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma].
Moreno Ortega E; Vallejo Casas JA; Mena Bares LM; del Real Núñez R; Maza Muret FR; Hidalgo Ramos FJ; Latre Romero JM
Rev Esp Med Nucl; 2008; 27(4):253-8. PubMed ID: 18682151
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of interference of thyroglobulin autoantibodies with assay of thyroglobulin using electrochemiluminescent assay].
Dai Q; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Aug; 28(4):780-3. PubMed ID: 21936380
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact.
Iervasi A; Iervasi G; Carpi A; Zucchelli GC
Biomed Pharmacother; 2006 Sep; 60(8):414-24. PubMed ID: 16959467
[TBL] [Abstract][Full Text] [Related]
12. [The correlation between endogenous TgAb and experimental Tg values in patients with differentiated thyroid carcinomas].
Tang GS; Xu J; Yu Y; Pan MZ; Wang JR; Yuan LP; Jiang T; Huang F; Jing CL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 42(6):856-60. PubMed ID: 22332559
[TBL] [Abstract][Full Text] [Related]
13. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
Rosario PW; Purisch S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
[TBL] [Abstract][Full Text] [Related]
14. The additive clinical value of combined thyroglobulin and antithyroglobulin antibody measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer.
Aras G; Gültekin SS; Küçük NO
Nucl Med Commun; 2008 Oct; 29(10):880-4. PubMed ID: 18769305
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
16. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal?
Mariotti S; Barbesino G; Caturegli P; Marinó M; Manetti L; Pacini F; Centoni R; Pinchera A
J Clin Endocrinol Metab; 1995 Feb; 80(2):468-72. PubMed ID: 7852506
[TBL] [Abstract][Full Text] [Related]
17. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.
Spencer C; Petrovic I; Fatemi S
J Clin Endocrinol Metab; 2011 May; 96(5):1283-91. PubMed ID: 21325460
[TBL] [Abstract][Full Text] [Related]
18. [Research on comparison of thyroglobulin autoantibody interference in measurement of thyroglobulin between electrochemiluminescent assay and radioimmunoassay].
Dai Q; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Apr; 29(2):242-6. PubMed ID: 22616166
[TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin and thyroglobulin autoantibodies measurement using the automated KRYPTOR® platform in patients with differentiated thyroid carcinoma.
Giovanella L; Toffalori E; Ceriani L; Caputo M; Verburg FA
Horm Metab Res; 2011 Sep; 43(10):728-30. PubMed ID: 21932179
[TBL] [Abstract][Full Text] [Related]
20. Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay.
Gao Y; Yuan Z; Yu Y; Lu H
Clin Biochem; 2007 Jun; 40(9-10):735-8. PubMed ID: 17462616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
